Drug intelligence / Profile preview

2,3-dihydroxycinnamic acid

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

2,3-dihydroxycinnamic acid, also known as o-caffeic acid, is a naturally occurring phenolic acid and a structural isomer of the common antioxidant caffeic acid (3,4-dihydroxycinnamic acid). It is found in various botanical and fungal sources, including the medicinal mushroom *Fuscoporia torulosa*. The compound is recognized for its potent antioxidant properties, demonstrating significant radical scavenging activity in ABTS, DPPH, and CUPRAC assays, often outperforming standard antioxidants like alpha-tocopherol and butylated hydroxyanisole (BHA). Additionally, 2,3-dihydroxycinnamic acid acts as a potent inhibitor of tyrosinase, the rate-limiting enzyme in melanin biosynthesis, which suggests potential therapeutic applications in treating skin hyperpigmentation and utility as a natural preservative in the food industry. Preclinical studies have also explored its cytotoxic effects against breast (MCF-7) and prostate (PC-3) cancer cell lines, as well as its ability to inhibit cholinesterase enzymes, indicating potential neuroprotective relevance.

Other names
o-Caffeic acid3-(2,3-dihydroxyphenyl)prop-2-enoic acid2,3-DHCA
02

Targets

TYR (Tyrosinase)

Beyond the preview

Go deeper on 2,3-dihydroxycinnamic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2,3-dihydroxycinnamic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call